CXCR3 and cancer: Although no adverse effect on tumour development was observed in our experiments as well as when AMG487 was systemically administered for 28 days in metastatic breast cancer (Walser et al, 2006), further effort will be required to examine this possibility, especially considering that CXCR3 blockade may be useful as a treatment strategy to interfere with metastasis in cancer patients.